Swanson D A, Quesada J R
Department of Urology, University of Texas M.D. Anderson Cancer Center, and Tumor Institute, Houston 77030.
Semin Surg Oncol. 1988;4(3):174-7. doi: 10.1002/ssu.2980040307.
We have used multiple interferon protocols to treat 274 patients who had metastatic renal cell carcinoma. Leukocyte (alpha) interferon in 50 patients produced 3 complete responses (CR) and 10 partial responses (PR), a 26% response rate that was nearly matched among the next 89 patients treated with recombinant alpha interferon (2 CR, 17 PR, 21%). Other types and combinations of interferon, even when coupled with cytotoxic chemotherapy or other biologic agents, did not produce better results. Interferon has definite activity against renal cell carcinoma, but clinical experience has not yet defined the optimal type, dose, and treatment schedule.
我们采用了多种干扰素方案来治疗274例转移性肾细胞癌患者。50例患者使用白细胞（α）干扰素治疗产生了3例完全缓解（CR）和10例部分缓解（PR），缓解率为26%；接下来接受重组α干扰素治疗的89例患者中，缓解率与之相近（2例CR，17例PR，21%）。其他类型的干扰素及其联合用药，即便与细胞毒性化疗或其他生物制剂联用，也未产生更好的效果。干扰素对肾细胞癌具有明确的活性，但临床经验尚未明确最佳的类型、剂量和治疗方案。
